POSTER: MDS-604 Improvement of Patient-Reported Fatigue in IMerge Phase 3 Trial of Imetelstat vs Placebo in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents
Year: 2023
Type: article
Authors: Mikkael Sekeres, Valeria Santini, Maria Díez-Campelo, Rami Komrokji, Pierre Fenaux, Michael Savona, Yazan Madanat, David Valcárcel-Ferreiras, Thomas Illmer, Anna Jonášová, Petra Bělohlávková, Antoine Regnault, Kristin Creel, Nishan Sengupta, Laurie Sherman, Tymara Berry, Souria Dougherty, Sheetal Shah, Qi Xia, Libo Sun, Ying Wan, Fei Huang, Annat Ikin, Shymala Navada, Faye Feller, Amer Zeidan, Uwe Platzbecker
Institutions: University of Miami, Sylvester Comprehensive Cancer Center, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Moffitt Cancer Center, Université Paris Cité, Hôpital Saint-Louis, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Vall d'Hebron Hospital Universitari, General University Hospital in Prague, University Hospital Hradec Králové, Geron (United States), Yale Cancer Center, Yale University, University Hospital Leipzig
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4386269923